Quotient Bioresearch has presented its extended lipid marker screen for assessing drug safety and efficacy at the Institute of Biomedical Sciences annual congress on 28-29 September 2009.
The range of markers included in the rapid screen extends the basic biochemistry panel used and provides a more comprehensive insight into the safety and efficacy of new drug compounds being evaluated for coronary vascular disease (CVD), coronary heart disease (CHD), diabetes and obesity.
With close to 200,000 deaths per annum in the attributed to diseases of the heart and circulatory system, they are the main cause of death in the UK.
Triglycerides, cholesterol, LDL-cholesterol and HDL-cholesterol are measured in the clinical setting to predict CHD.
They are also used by pharmaceutical companies in the development of new drugs.
Quotient has validated a rapid screening panel that adds to this with: Apo A-1, Apo B-100, Apo C-Ill, Lp(a) (Lipoprotein a), and NEFA (Non-esterified Fatty Acids).